Personalized medicine: new genomics, old lessons by Offit, Kenneth
REVIEW PAPER
Personalized medicine: new genomics, old lessons
Kenneth Ofﬁt
Received: 10 February 2011/Accepted: 30 May 2011/Published online: 26 June 2011
  The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Personalized medicine uses traditional, as well
as emerging concepts of the genetic and environmental
basis of disease to individualize prevention, diagnosis and
treatment. Personalized genomics plays a vital, but not
exclusive role in this evolving model of personalized
medicine. The distinctions between genetic and genomic
medicine are more quantitative than qualitative. Personal-
ized genomics builds on principles established by the inte-
gration of genetics into medical practice. Principles shared
by genetic and genomic aspects of medicine, include the use
of variants as markers for diagnosis, prognosis, prevention,
as well as targets for treatment, the use of clinically vali-
dated variants that may not be functionally characterized,
the segregation of these variants in non-Mendelian as well
as Mendelian patterns, the role of gene–environment
interactions, the dependence on evidence for clinical utility,
the critical translational role of behavioral science, and
common ethical considerations. During the current period
of transition from investigation to practice, consumers
should be protected from harms of premature translation of
research ﬁndings, while encouraging the innovative and
cost-effective application of those genomic discoveries that
improve personalized medical care.
Introduction
Personalized medicine did not begin in the post-genome
era. One colleague, trained before Watson and Crick’s
landmark discovery, asked if she had been practicing
‘‘impersonal medicine’’ all those years. As one historian
has put it: ‘‘The new language of genomics, as applied to
medicine, is less a revolution than an evolution’’ (Steele
2009). The current enthusiasm, and occasional ‘‘hype,’’
about personalized genomics follows several decades of
scientiﬁc discovery and clinical translation in human
genetics. Rather then constituting a new paradigm, per-
sonalized genomics is best viewed as incremental to the
model built over several decades of the practice of genetic
medicine. In this Perspectives, we will focus on the lessons
learned from genetic medicine, which provide a solid
foundation to deﬁne the scientiﬁc and clinical challenges
inherent in the application of genomics to personalized
medicine.
The relationship of genomics and personalized medicine
There has long been interest in personalizing medicine.
Hippocrates individualized diagnosis and treatment, for
example, by giving cold food to a ‘‘phlegmatic’’ person
(Steele 2009). Today, personalized medicine, informed by
a molecular understanding of disease, has brought new
classiﬁcation systems as well as more effective preventive
and therapeutic interventions. Personalized medicine is ‘‘a
form of medicine that uses information about a person’s
genes, proteins, and environment to prevent, diagnose, and
treat disease’’ (National Cancer Institute 2011). Thus, a
physician—even a pre-genomics trained general practi-
tioner—can deliver personalized care in the absence of
DNA proﬁles. This distinction is often garbled. For
example, in the version of H.R. 5440 (re-introduced in the
last Congress and originally introduced by then-Senator
Obama) personalized medicine is deﬁned as ‘‘any clinical
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ventive, diagnostic, and therapeutic interventions that use
genome and family history information to improve health
outcome’’ (H.R. 5440, 2010). Such a deﬁnition of person-
alized medicine, while politically correct, incorrectly omits
vital non-genetic components including environmental or
occupational exposures.
Another semantic distinction, with enormous regulatory,
ethical, and practical implications, grows from our
assumption that personalized genomics must meet the same
standards as other components of personalized medicine.
Some commercial entities sought to deﬁne a non-medical
role of personal genomics as a ‘‘recreational’’ or ‘‘infor-
mation-seeking’’ pursuit. In December 2008, a multidisci-
plinary work shop was convened by the National Institutes
of Health and the Centers for Disease Control to review the
scientiﬁc foundation for using personalized genomics as a
component in personalized medicine. The attendees
included investigators in human genetics and genetic epi-
demiologic research, leadership at NIH and CDC, as well
as the senior leaders of the for-proﬁt ‘‘direct-to-consumer’’
(DTC) genomic proﬁling companies (Khoury et al. 2009).
At one point in the public session of that meeting, I had the
opportunity to ask the panel of corporate leaders if they
intended genomic proﬁles ultimately to be reimbursed by
third party carriers as part the personalized medical man-
agement of individuals. At that time, not that long ago, the
unanimous answer of the CEO’s was that their personalized
genomics ‘‘spit kits’’ were deﬁnitely not medical tests and
‘‘medicalization’’ was not part of their business model.
However, in the past year, spurred by a sharply critical
House Committee on Energy and Commerce Subcommit-
tee on Oversight and Investigations report on DTC mar-
keting of personalized genomics, as well as open hearings
and device notiﬁcation letters sent by the FDA (Vorhaus
2010), the mission and marketing strategy of several for-
proﬁt genomics proﬁling providers underwent post-tran-
scriptional modiﬁcation. Working with laboratories that are
CLIA approved, some companies began seeking a role as
providers of pre-symptomatic or diagnostic medical tests.
While other articles in this volume explore the broad issues
of DTC marketing of genomic proﬁling, our focus here is
on the scientiﬁc foundation of genomic research and per-
sonalized medicine. In this discussion, we will assume that
personalized genomics plays a vital, but not exclusive role
in an evolving model of personalized medicine.
The scope of scientiﬁc challenges facing the use
of personalized genomics in medicine
The scientiﬁc foundation for personalized genomics draws
on a range of disciplines including, among others, basic
genetics, population genetics, genetic and clinical epide-
miology, behavioral science, and emerging regulatory sci-
ence. The applications of genetics and genomics in
personalized medicine have included elements of risk
assessment, diagnosis, prognosis, and treatment (Table 1).
The path from concept to clinical use in each of these
domains involves basic, translational, and regulatory sci-
ence (Hamburg and Collins 2010). The fusion of personal
genomics and medicine is informed by reference to the
model of four phases of scientiﬁc research leading from
discovery to improved health outcomes. The ﬁrst phase
(T1) includes discovery and replication of ﬁndings, the
second (T2) evaluates new tests for validity and utility, the
third phase (T3) evaluates best approaches for diffusion
and dissemination of tests, and the ﬁnal phase of translation
from bench to bedside (T4) involves research addressing
population impact, effectiveness, and economic aspects
(Khoury et al. 2007). Across these four phases, research
studies evaluate personalized genomics using the ‘‘ACCE’’
framework: analytic validity, clinical validity, clinical
utility, and ethical, legal, and social implications (Haddow
and Palomaki 2004). This scientiﬁc framework encom-
passes but does not emphasize the notion of ‘‘personal
utility’’ of medical tests, which, we will shortly argue, is
not a unique feature of ‘‘spit test’’ genomics, but has been a
part of medical practice for decades.
The lessons of ‘‘personalized genetics’’ relevant
to ‘‘personalized genomics’’
The venerable ﬁeld of genetics refers to the study of
single genes, while the emerging ﬁeld of genomics refers
to the study of all of a person’s genes (Guttmacher and
Collins 2002; National Human Genome Research Institute
2010). Distinguished laboratory scientists increasingly
speak about the new promise of knowledge of one’s
‘‘personal genome,’’ predicting a time when genomics
will provide warnings and inform preventive actions.
Scholars debate whether we are still waiting for the
genomics revolution, and if its role in personalized
medicine has been overblown (Marshall 2011). Of course,
the reality is that many clinicians have been using
genetics to personalize practice for decades. As will be
argued here, the distinctions between genetics and geno-
mic medicine are more quantitative than qualitative. The
traditional dogma is that genetic and genomic medicine
are qualitatively different for a variety of reasons
including the non-directive nature of genetic counseling
for single gene disorders, the use of genetic information
for diagnosis in contrast to the use of genomic informa-
tion (including somatic changes in cancers) as complex
biomarkers of risk and outcome, and the interplay of
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(Guttmacher and Collins 2002; Khoury 2003). As will be
argued here, virtually all of these ‘‘unique’’ features of
genomics in medicine were presaged and have been
incorporated into the translation of genetics to medicine.
Over the past decade, the clinical translation of genetics
went beyond the largely pediatric and reproductive
emphasis of medical genetics, and became part of the
core practice of a many ﬁelds of medicine, most notably
cancer prevention and management (Ofﬁt 1998). While
the computational challenges of genomics are especially
daunting, the translation of genomics to the clinic derives
squarely from genetics practice. Indeed, single or multi-
plexed genetic proﬁles, have been applied to pre-symptom-
atic risk assessment, as well as to diagnostic, prognostic,
and therapeutic application in several ﬁelds, including
cancer care. Genetic proﬁling in personalized medicine is
now de rigueur in many medical disciplines where it has
shifted traditional paradigms (Green and Guyer 2011). In
oncology, the use of pre-symptomatic genetic testing and
‘‘targeted therapies’’ tailored to genetic proﬁles of tumors
is part of recommended evaluation for cancers of the colon,
lung, breast and other sites (American Society of Clinical
Oncology 1996, 2003, 2010; Robson and Ofﬁt 2007;
Macconaill and Garraway 2010; McDermott et al. 2011). It
is therefore instructive to review some of the insights
gleaned from the recent period of scientiﬁc discovery and
translation to practice of genetic medicine, since the les-
sons learned are directly relevant to the challenges facing
personalized genomics.
Table 1 Examples of genetic and genomic testing in personalized medicine
Pre-symptomatic risk assessment
BRCA1/2 testing for breast cancer
a
Lynch syndrome testing for hereditary colon cancer
b
Long QT interval
c,d
Spinal Muscular Atrophy
e
Diagnosis
Beta thalassemia
f
Fusion genes and rearrangements including BCR-ABL, E2A-PBX1, TEL-AML1, and MLL in pediatric leukemia
g
Gene expression proﬁles deﬁne subtypes of breast cancer
h
Human Papilloma Virus detection
i
Hepatitis C detection
j
PCR detection of micro-organisms (bacteria, fungi)
k
Prognosis
Fragile X syndrome (number of trinucleotide repeats predicts severity)
l
Gene expression signatures and prognosis in breast cancer
m
Gene expression analysis and lymphoma prognosis
n
Treatment and pharmacogenomics
Therapies for targeted gene mutations in cancer
o
EGFR point mutations in lung cancer and glioblastoma and cetuximab, geﬁtinib, erlotinib, panitumumab, lapatinib treatment
KIT, PDGFR mutations in sarcoma, glioma, liver and renal cancer, melanoma and imatinib, nilotinib, sunitinib, sorafenib treatment
BRAF mutations in melanoma treated by RAF inhibitors
BCR-ABL translocation in chronic myelogenous leukemia treated by imatinib
KRAS wild-type status correlated with resistance to EGFR inhibition
PARP inhibitors in BRCA mutant breast, ovarian, prostate and pancreatic cancer
Herceptin (Trastuzumab) in HER2 ? breast cancer
Pharmacogenomic applications
p
CYP 2C19*2 variant (rs4244285) associated with diminished clopidogrel response
q
Rs2395029 testing for HLA-B*5701 allele, correlated with hypersensitivity to abacavir treatment for HIV? patients
r
a Robson and Ofﬁt (2007),
b EGAPP (2009a),
c Napolitano et al. (2005),
d Lehnart et al. (2007),
e Prior et al. (2008),
f Galanello and Origa
(2010),
g Carroll et al. (2003),
h Sorlie et al. (2001),
i Nicol et al. (2010),
j Pham et al. (2010),
k Tsalik et al. (2010),
l Sherman et al. (2005),
m Kim and Paik (2010),
n Rosenwald et al. (2002),
o Macconaill and Garraway (2010),
p U.S. Food and Drug Administration (2011),
q Shuldiner
et al. (2009),
r Colombo et al. (2008)
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even in the absence of a complete understanding
of their functional biologic signiﬁcance
The use of linkage or ‘‘reverse genetics’’ led to discoveries
of the basis of single gene disorders, such as hemophilia,
cystic ﬁbrosis, and breast cancer (reviewed in Botstein and
Risch 2003). In the case of BRCA1, over 15 years after its
discovery, its myriad cellular roles continue to be deﬁned
(Boulton 2006), complicating prediction of the functional
(hence clinical) signiﬁcance of missense variants routinely
detected (Spearman et al. 2008). The same limitation
applies for the estimated 50,000–200,000 single nucleotide
polymorphisms (SNPs), which may contribute to disease
(Orr and Chanock 2008). Non-synonymous SNPs in exons
are the most amenable to estimation of their functional
signiﬁcance, however, even synonymous SNPs can effect
mRNA stability and alter splicing signals, and have been
linked to diseases such as androgen-insensitivity syndrome
and thrombasthenia (Chamary et al. 2006). SNPs in introns
and regulatory regions, and SNPs in ‘‘gene deserts’’ may
affect gene regulation, as in the case of prothrombin dis-
orders, schizophrenia, or colon cancer (Poort et al. 1996;
Law et al. 2006; Pomerantz et al. 2009). Recognizing that
most SNPs are merely ‘‘markers’’ of a genetic lesion, and
that frequencies of disease-associated SNPs may be
obscured or falsely elevated as a result of population het-
erogeneity, the lack of a precise biological understanding
of genetic or genomic associations limits but does not
preclude their clinical application. In the mid 1990s, we
and others counseled families regarding prophylactic
mastectomies based only on markers linked to the BRCA1
locus. Today, we and others will soon offer testing for risk
modifying variants affecting BRCA2 penetrance and ex-
pressivity (Gaudet et al. 2010; Antoniou et al. 2010), even
in the absence of knowledge of their function. The proof of
clinical utility of genetic or genomic predictive markers
does not depend on a complete biological functional
understanding of the genetic variant in question, although
such an understanding remains critical for pharmacologic
targeting.
Human disease susceptibility is the result of rare
genetic variants of high penetrance as well
as common genomic variants of low penetrance
After more than a decade of debate between the Common
Disease, Common Variant (CDCV) and Common Disease
Rare Variant (CDRV) camps, it is now evident that both
sides have won. This debate is reminiscent of a similar
dispute, a century earlier, between the ‘‘Mendelians’’ and
the ‘‘Biometricians,’’ ultimately settled by RA Fisher who
established that multiple genes in additive fashion—and
following Mendel’s laws—could account for continuous
variation of phenotypic expression (Provine 2001). With the
completion of dozens of genome wide association studies, it
is now clear that the bulk of excess familial risk of many
diseases is not accounted for by common variants, the so
called ‘‘missing heritability’’ of human disease (Maher
2008). This is not to diminish the biological insights made
by the GWAS studies, which have elucidated hidden
pathways of important etiologic signiﬁcance. For example,
GWAS studies identiﬁed the complement pathway in age-
related macular degeneration and autophagy pathways in
Crohn’s disease, as well as a number of pathways not evi-
dent from the somatic genetics of cancer (Carvajal-Car-
mona 2010; Stadler et al. 2010). Most in the ﬁeld have come
to appreciate that both the common and rare variant
hypotheses have contributed signiﬁcantly to our under-
standing of human disease susceptibility (Schork et al.
2009). Nonetheless, the search continues for the missing
heritability of disease, focusing on gene–environment
interactions, germline copy number variants, epigenetic and
epistatic events, and, most recently, rare variants missed by
prior GWAS and linkage approaches but resolvable using
next generation sequencing technologies (NGS). The cur-
rent interest in NGS approaches to discover rare variants,
successful thus far in uncovering rare variants associated
with recessive syndromes, has proven more challenging for
autosomal dominant syndromes, for example, adult-onset
cancer families wild-type for known predisposition genes.
The lesson being learned in this process, consistent with the
overall theme of ‘‘new genomics, old lessons,’’ is that
unraveling the personalized genome through NGS often
relies on traditional genetic approaches. The tens of thou-
sands of coding variants discovered by the average exome
scan may be reduced by an order of magnitude by co-seg-
regation of the variant in an affected kindred. The proof of
association of these genomic variants will rely on causal
evidence of functional signiﬁcance of the genetic mutations
observed. Similarly, the proof of ‘‘actionability’’ of geno-
mic variants at the clinical level will largely rely on empiric
approaches established in the era of single gene discovery,
validation, and clinical translation.
Genetic and genomic variants may manifest
phenotypically in non-Mendelian patterns
Another lesson learned from the ‘‘personalized genet-
ics’’ era that should inform the translation of genomics to
practice stems from observations of non-Mendelian pat-
terns of inheritance of susceptibility to complex human
traits. Such phenomena as imprinting, de novo germline
mutations, and epigenetic mechanisms of inheritance are
still being deﬁned as they apply to the transmission
genetics of single gene disorders. While the de novo
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and hereditary endocrine tumors are 30–50% (Garber and
Ofﬁt 2005), the de novo mutation rates for the most fre-
quent susceptibilities to cancers of the breast and colon
remain unclear. De novo germline copy number variation
as a mechanism of susceptibility to autism, reviewed in this
issue, was a hallmark early discovery of the genomics era
(Sebat et al. 2007), and de novo point mutations have
recently been observed in individuals affected by mental
retardation (Vissers et al. 2010). Studies of de novo
genomic variation have not yet been performed for many
complex human traits. Non-Mendelian patterns of trans-
mission of epigenetic silencing of genes associated with
colon cancer (e.g. MLH1), can create a conundrum for
genetic counseling due to the observation that epimutation
of the promoter of this gene may vary from one generation
to the next (Hitchins 2010). Mechanisms of epigenetic
silencing of shared promoters of adjacent genes (e.g.
MSH2, PTEN/KILLIN) are still being described (Hitchins
2010; Bennett et al. 2010). Phenomena such as promoter
methylation in the germline, not detected on ﬁrst genera-
tion genome scans, will need to be taken into consideration
as personalized genomic proﬁles evolve.
The genomic model of human disease, like
the multifactorial genetic model, will incorporate
environmental as well as genetic modiﬁers
The genetics era produced important insights into the
interaction of genetic and environmental factors, for
example the metabolism of carcinogens mediated by
xenobiotic genes (Shields and Harris 2000), as well as the
ﬁrst models of pharmacogenetic variants of drug metabo-
lism (Katz and Bhathena 2009). A challenge in the tran-
sition from genetics to genomics is the complexity of
information; genomic variants may play etiologic roles for
a spectrum of diseases, and interact with other variants and
environmental factors (Conti et al. 2010). Computational
models will need to be developed to determine how po-
lygenes and environmental factors interact to perturb cel-
lular regulatory networks, affecting cellular phenotypes
and determining a rationale for targeted prevention of
disease (Schadt et al. 2009).
Analytic validity of genotyping cannot be taken
for granted
Hard lessons were learned during the ‘‘personalized
genetics’’ era about the critical translation of genotyping
from the research laboratory to the clinic (T2 phase of
‘‘laboratory science’’) (Khoury et al. 2009). Catastrophic
results may follow an analytic failure of a single genotype.
In one such case, a miscall of a BRCA mutation led to an
unnecessary surgery and legal action by the patient against
the testing laboratory (Peres 1999). At our institution,
where the internal clinical lab repeated all positive (and
true negative) genotyping results before risk reducing
surgeries were recommended, both analytic and post-ana-
lytic errors by external academic and commercial labora-
tories were noted in the years following the initial
description of the BRCA genes. In the genomics era, similar
reporting inconsistencies have also been observed. Several
individuals were sent widely divergent results when the
same sample was tested in different commercial laborato-
ries, indicating suspected analytic or post-analytic error
(Fleming 2008; Davies 2008; Ng et al. 2009).
Encouraged by calls from professional societies (e.g.
ASCO 2010), and as required by law in some states such as
New York, the same quality assurance standards required
for clinical genetic tests are being requested of genomic
‘‘proﬁles’’ (Vorhaus 2010; Hamburg and Collins 2010). It
is now evident that the ‘‘T2’’ phase of clinical laboratory
science will not be overlooked in the incorporation of
genomics to personalized medicine.
Behavioral science is needed to inform the translation
of genetics (and genomics) to preventive practice,
in order to maximize beneﬁt and to avoid
the consequences of incomplete risk communication
One of the most important lessons of the ‘‘personalized
genetics’’ era, emerging largely from NHGRI supported
research, is that even an analytically and clinically validated
genetic test may fail as a tool for prevention or screening
unless it is translated to a behavioral action by the at-risk
individual. A large part of the art as well as practice of
genetic counseling is built on a foundation of behavioral
research. A goal of applied research in this area has been to
minimize the adverse impact of testing, and promote the
uptake of recommended primary or secondary preventive
interventions following testing (Heshka et al. 2008). Initial
reports of self-administered genomic ‘‘proﬁling’’ conﬁrm
that compliance with such interventions as a lower fat diet
and exercise were positively impacted by sharing results
with a physicians (Bloss et al. 2011). Researchers and
practitioners during the era of personalized genetics also
discovered that the diffusion of genetic information in
families may be highly variable. Families may be dys-
functional; not every individual wants to know genetic
information, or wants their relatives to know. Such conﬂicts
can enmesh the genetics practitioner or researcher in the
liability trap of the so-called ‘‘duty to warn’’ at-risk relatives
(Ofﬁt et al. 2004).
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information varies and depends on context
There is variation both within families and between indi-
viduals regarding the processing of probabilistic risk
information, and ability to act on it. For example, Craig
Venter pointed out: ‘‘…We have, in truth, learned nothing
from the genome other than probabilities. How does a 1 or
3 percent increased risk for something translate into the
clinic? It is useless information’’ (Spiegel 2010). From the
experience of genetic counseling, we have learned that
perceived utility of probabilistic information can depend on
the context of presentation. For example, does the 3%
increase in risk referred to above pertain to absolute or
relative risk? A 3% increase in absolute risk of pancreatic
cancer, observed in BRCA2 mutation carriers, from 1 to
4%, is quite signiﬁcant, while a 3% increase in relative risk
for pancreatic cancer due to a common SNP (relative risk
1.03 compared to 1.0) indeed seems negligible. For cancer
at least, not all SNPs have negligible relative risks (Stadler
et al. 2010). For example for both testicular cancer and
myeloproliferative disease the increased risks are on the
order of two to threefold (Stadler et al. 2010). In addition,
while risks are generally quoted for the common hetero-
zygote, the risks for the rare homozygote may be higher; in
addition epidemiologic concepts of attributable risk are
often misleadingly applied in genomics (Ofﬁt 2009).
Finally, research has shown that psychosocial context is
important for translation of genetic (and genomic) risk
information (Heshka et al. 2008).
Genetic or genomic markers with proven analytic
and clinical validity and a strong biological rationale
may not meet evidence-based standards of clinical
utility
Over the past two decades clinical investigators have
established an evidence base for the utility of genetic tests
in a variety of medical contexts. The same will apply to
genomic tests. In the area of breast and colon cancer
genetics, for example, the clinical utility of genetic testing
has been documented (Evaluation of Genomic Applica-
tions in Practice and Prevention 2009a, b; Domchek et al.
2010). Numerous professional organizations have con-
ducted evidence reviews, and at the federal level, the need
to produce evidence-based recommendations on validity
and utility of genomic applications in medicine was rec-
ognized by the creation of the Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) working
group (Teutsch et al. 2009). The EGAPP working group
adapted the methods of the US Preventive Services Task
Force (USPSTF). It is important to note that these and other
groups’ evidence-based evaluations did not all reach
anticipated conclusions. Of the ten comprehensive reviews
carried out or in preparation by EGAPP, all but one have
been unfavorable or neutral (Marshall 2011); several of
these reports have yet to be published. For example, there
was mixed evidence regarding the association between
CYP450 genotypes and selective serotonin uptake inhibitor
(SSRI) metabolism, efﬁcacy, and tolerability in the treat-
ment of depression (Evans and Khoury 2007; Agency for
Healthcare Research and Quality 2007), and insufﬁcient
evidence of clinical utility of UGT1A1 genotyping to pre-
dict toxicity of irinotecan therapy (Evaluation of Genomic
Applications in Practice and Prevention 2009b). In evalu-
ating the clinical utility of Factor V Leiden (FVL) testing
alone, or in combination with prothrombin G20210A
analysis, there was no direct evidence found to support
testing for these mutations leading to improved clinical
outcomes in adults with a history of venous thromboem-
bolism or their adult family members (Evaluation of
Genomic Applications in Practice and Prevention 2011).
Similarly, pharmacogenomic testing to guide warfarin
therapy, added to the product label in 2007 by the FDA,
was not approved for Medicare reimbursement in mid-
2010; large trials to establish the evidence for this example
of pharmacogenetics are still in progress (Klein et al. 2009;
Conti et al. 2010; Meckley et al. 2010). Despite consider-
able enthusiasm and a very strong biologic rationale, recent
results from two large randomized trials surprisingly failed
to support the clinical utility of CYP2D6 testing accom-
panying tamoxifen treatment of women with breast cancer
(Rae et al. 2010; Leyland-Jones et al. 2010). These ﬁndings
underscore the critical importance of an evidence base to
inform the incorporation of genomics into the practice of
medicine, and the potential dangers of self administration
of these tests without expert interpretation. The application
of traditional evidentiary standards to genomics also may
stir debate. For example, it appears that funding for the
EGAPP program itself will be seriously diminished in the
near future (Marshall 2011). Such developments are par-
ticularly difﬁcult at a time when the scientiﬁc context for
the evaluation of the clinical utility of personalized
genomics is comparative effectiveness research, wherein
the additive role of genomics is measured compared to
existing medical practices (Wilensky 2006).
The promise of personalized, genomic medicine should
be informed by the past decade of experience
developing genetically targeted therapies
In the era of genetically targeted agents, the cost for
development of ‘‘biological’’ therapies is fast approaching
the $1.2 billion cost per drug for conventional pharma-
ceutical development (Malik and Khan 2010). At the same
time, large pharmaceutical companies have come to view
8 Hum Genet (2011) 130:3–14
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sword. While genomic targeting may identify the propor-
tion of non-responding patients who cause up to 50% of
new drugs to fail phase III trials, it will also narrow the
target population, decreasing the potential for ‘‘block-
buster’’ drugs. For example, when KRAS genotyping of
colon tumors was shown to correlate with resistance to
pharmacologic inhibition of EGFR, the indicated uses for
those drugs diminished. An emerging concern in the
genomics era is that some targeted drugs for ‘‘orphan
diseases’’ (e.g. PARP inhibitors for BRCA mutant tumors)
may not meet proﬁtability thresholds set by pharmaceutical
companies, or may be marketed for more broadly deﬁned
phenotypes where efﬁcacy is more uncertain. While it is
true that personalized genomics may improve treatment
efﬁcacy and decrease toxicity, a lesson of the genetics era
is that the economic hurdles of the biological drug devel-
opment pipeline remain signiﬁcant (Malik and Khan
2010).
Concepts such as ‘‘personal utility’’ and non-traditional
modes of delivery of risk information are not new
to personalized genomics
Both genetic and genomic tests may be provided within or
outside the realm of health care providers, and both may
be deemed to be of value to the individual even if there is
no available medical intervention. Distinctions need to be
made between DTC marketing of genetic tests with
referral to health care professionals, and DTC provision of
these services circumventing the health care system
(American Society of Clinical Oncology 2010). There is
emerging experience with provision of genetic counseling
augmented by telemedicine and virtual interactions with
health care professionals (Zilliacus et al. 2010). The
explicit bypassing of health professionals in the provision
of genetic and genomic information of uncertain validity
and utility raises risks of false reassurance or false alarm,
and consequent adverse psychological sequelae (Ofﬁt
2008). Several decades of genetic counseling have resulted
in the conclusions by meta-analyses of remarkably few
adverse psychological sequelae (Braithwaite et al. 2004;
Heshka et al. 2008) following counselor-informed genetic
testing. A recent study of 2,037 individuals who self-
administered DTC genomic risk proﬁling with no formal
role of genetics professionals found a correlation in test-
related distress with lifetime risk (Bloss et al. 2011). Of
note, 57 individuals in this series (2.7%) experienced
severe (clinically signiﬁcant) test-related distress by psy-
chometric scales. In the era of genomics, as in genetics,
even one strongly adverse reaction resulting in harm to the
individual can have profound psychological or even legal
consequences.
An implied precept of clinical genetics has been the
notion that ‘‘personal utility’’ of a genetic test hinges on an
assumption of clinical validity and utility. Implicit in
modern medical practice is the principle that personal
utility may be derived from knowledge of the risk or
diagnosis of untreatable disorders, such as Huntington
disease (Wiggins et al. 1992) or Li Fraumeni syndrome
(Lammens et al. 2010). Recent ﬁndings regarding testing
for Alzheimer disease conﬁrm those prior ﬁndings; genetic
testing of such individuals can be performed without
immediate adverse sequelae (Green et al. 2009). However,
tests of unknown clinical validity or clinical utility would
logically be unsuited to result in ‘‘personal utility,’’ unless
the perceived utility was based on a misunderstanding of
the meaning of the test. In an instructive case, the ﬁrst
individual to have his genome sequence publically dis-
seminated, admitted that he initially misinterpreted the
clinical and personal utility of a non-synonymous variant
of unknown signiﬁcance in his BRCA1 gene, until he
consulted a specialist (Watson 2009). Studies of ‘‘personal
utility’’ of validated genetic tests were performed at the
outset of the genetics revolution; this research concluded
that an indeterminate test result for a lethal disease can
have the most severe sequelae (Wiggins et al. 1992). This
is a lesson especially relevant in the ‘‘genomic’’ era, since,
at the present time most, if not all of the common variants
for common diseases are, for the most part, not clinically
actionable (Evaluation of Genomic Applications in Prac-
tice and Prevention 2010; Wellcome Trust Case Control
Consortium 2007; Stadler et al. 2010; Manolio 2010).
Epistatic interactions between these variants as well as
interactions with environmental factors are not yet known,
further limiting the immediate prospects for personal utility
of self-administered genomic proﬁles.
As was the case for genetic counseling for complex
disorders, new models for ‘‘genomic counseling’’
are most responsibly offered ﬁrst in a research
and then a clinical context
The description of the efforts to deduce potentially
pathogenic mutations from the genome of a single
40-year-old male (Ashley et al. 2010) supports the ratio-
nale for imbedding these efforts in a research context. The
reasons for caution revealed in that study include: limi-
tations of current sequencing platforms (e.g. failure to
detect structural genomic changes or to distinguish
mutations on the same or different chromosomes), the
absence of a central repository of rare and disease-causing
variants, and the need for longitudinal follow-up to update
counseling based on new information (Ormond et al.
2010). The clinical translation of the estimated 50–100
variants implicated in inherited disorders, and present in a
Hum Genet (2011) 130:3–14 9
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2010) will require improved human reference sequence
quality, variation, and annotation, which at present require
extensive manual analysis and orthogonal validation of
variants to derive clinical meaning from the data (Mardis
2010). Current clinical models and training do not readily
allow for the timely communication of such a volume of
genetic information to individuals (Ormond et al. 2010).
While unraveling of the genomes of a dozen cancer types
has led to the discovery of several new oncogenes and
tumor suppressor genes (e.g. IDH1 mutations in leukemia
and glioblastoma, DPP10 deletions in mesothelioma,
novel translocations in prostate cancer), the translation of
these ﬁndings to personalized therapeutics also remains a
research-in-progress (Weinberg 2010). The interpretation,
counseling, and medical implications resulting from
analysis of individual germline or cancer-derived genome
sequences will likely entail higher human costs and lia-
bilities than costs to generate the genotypes (Mardis
2010).
As these data on rare germline and somatic variants
continues to accumulate, the path for clinical validation
will be built using a multidisciplinary approach to genomic
counseling. The spectrum of evidentiary standards required
for personalized medicine is illustrated by two panels
tasked to review personalized genomic data in different
research and clinical contexts. For the EGAPP Working
Group, the criteria for clinical utility of testing were the
‘‘high bar’’ established by evidence-based reviews. The
reviews of a single or panels of genetic variants took a year
or more to complete, and often failed to document evidence
of clinical utility (Evaluation of Genomic Applications in
Practice and Prevention 2009a, b, 2010, 2011; Evans and
Khoury 2007). However, for a study using a panel of SNPs
to assess the impact of personalized genomics on 4,372
individuals, the scientiﬁc advisory board was tasked with
evaluating clinical validity of the SNP and if the SNP was
potentially actionable (Keller et al. 2010). In just a few
meetings, 17 SNPs were approved (2 not approved) for
inclusion. Because genomic proﬁling was being offered in
the context of a longitudinal research study, the ethical and
scientiﬁc conduct of the study allowed for communication
of genomic markers of unproven clinical utility. Such an
investigational path for the translation of personalized
genomics resembles that proposed in the early days of
BRCA analysis, when testing was encouraged in the context
of longitudinal research studies (American Society of
Clinical Oncology 1996). It is also consistent with current
emerging consensus in the bioethical community that the
issue is no longer if genomic information should be
returned to consenting individuals in the context of
research, but how to do this while avoiding harm (Brede-
noord et al. 2011).
The same range of ethical issues apply to ‘‘personalized
genomics’’ as to personalized genetics
The era of personalized genetics brought with it a focus on
ethical implications of research and the process of informed
consent. For example, the informed consent for genetic
testing for cancer includes 14 elements (American Society
of Clinical Oncology 2010). These same elements, relating
to potential risks and beneﬁts, are relevant to genomic
testing and research. In addition, a move toward transpar-
ency of disclosure now requires scientists, physicians, and
genetic counselors who are either directly employed or
derive beneﬁt from for-proﬁt genomic testing companies to
reveal those conﬂicts of interest. Consumers are now being
marketed to seek guidance from professionals who have
other than a ﬁduciary responsibility to them as patients.
Disclosure of personal conﬂicts of interest is a key element
in the provision of personalized medicine. Another
emerging ethical issue bearing on the translation of genetics
and genomics to personalized medicine is equity and
access; there is the risk that these technologies will be
available only to the afﬂuent (Mardis 2010). This, in fact,
was the experience in the clinical dissemination of preim-
plantation genetic diagnosis (Ofﬁt et al. 2006). Finally, as
mentioned, there remains inconsistency in the ethical and
legal deﬁnitions of ‘‘duty to warn’’ family members at
potentially increased genetic—or genomic risk—of a dis-
ease or adverse outcome (Ofﬁt et al. 2004). In an era of over
a half dozen ‘‘black box’’ FDA warnings, and over 60 labels
with information regarding dosing or toxicity guidance
based on genetic markers, it is known that risks for toxicity
or altered metabolism follow Mendelian patterns. The unit
of concern in genomics, as in genetics, is the risk to the
family and not simply the individual.
Concluding comments
There is little debate that the extraordinary progress in
genome science over the past decade, coupled with the
declining cost of sequencing technologies, has brought the
promiseofpersonalizedmedicinecloserthanever.However
it still remains true, as Harold Varmus once said, that
genomics is more a way to do science, not medicine (Wade
2010). Many in the ﬁeld also share David Altshuler’s
skepticism about the promise of personalized medicine
when it comes to common, complex diseases (Dougherty
2010). While it is true that the Human Genome Project has
not yet directly affected the health care of most individuals,
there have been dramatic examples of genetically targeted
treatment and prevention, notably in the ﬁeld of oncology
(Collins 2010; Macconaill and Garraway 2010; Green and
Guyer 2011). The past decade of translation of genetics to
10 Hum Genet (2011) 130:3–14
123personalized medicine provides a roadmap to inform the
incorporation of genomics into clinical practice during the
decade ahead. For common variants, the paradox remains
that that personalized medicine now requires population-
sized experiments to explore common polygenes, environ-
mental factors, and clinical endpoints (Orr and Chanock
2008). For rare disease predisposition syndromes and indi-
vidual cancer genomes, the progress of sequencing tech-
nologies has made personalized genomics a reality
(Meyerson et al. 2010). The computational and counseling
challenges resulting from the emerging deluge of next
generation sequencing data constitutes a barrier that will
need to be surmounted to translate genomics research to
practice, and to emerge from what Elaine Mardis has called
the era of the $1,000 genome and the $100,000 analysis
(Mardis 2010). Throughout this process, more clinical
research in the validation (T2) and cost effectiveness (T4)
end of the spectrum will be required to produce the evi-
dentiary database to inform the practice of personalized
medicine (Khoury etal. 2007).Commercial genomic testing
labs, as well as genomics-based pharmaceutical companies
will require this evidentiary foundation to obtain reim-
bursement for medical services. During this period of tran-
sition from investigation to practice, efforts will be needed
to protect consumers against potential harms of premature
translation of research ﬁndings, while encouraging innova-
tive and cost effective application of those genomic dis-
coveries that improve personalized medical care.
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